Calif. Sup. Ct. Refuses to Review Wyeth-Generic Duty-to-Warn Ruling

SACRAMENTO, Calif. - The state's highest court has refused to weigh in on whether brand-name drug manufacturers owe a duty to provide warnings to consumers who take the drug and those whose doctors foreseeably rely on the brand named drug's product information when prescribing a generic equivalent. Conte v. Wyeth Inc., et al., No. S169116 (Calif. Sup. Ct.).

According to the State Supreme Court's Jan. 21 announcement, a petition to review the First District Court of Appeal ruling that extended the duty to Reglan manufacturer Wyeth under a theory of negligent misrepresentation was denied without comment.

The First District …